| [1] |
Mao W, Jiang X, Guo S, et al. Splenic artery steal syndrome in patients with liver cirrhosis: A retrospective clinical study[J]. Med Sci Monit, 2023, 29: e938998.
|
| [2] |
Chen SH, Tsai SC, Lu HC. Platelets as a gauge of liver disease kinetics[J]. Int J Mol Sci, 2022, 23(19): 11460.
|
| [3] |
Satai M, Vaidya A, Rathod K, et al. Partial splenic artery embolization for the management of symptomatic hypersplenism in portal hypertension: clinical insights from a case series[J]. J Clin Exp Hepatol, 2024, 14(5): 101435.
|
| [4] |
Sun X, Zhang A, Zhou T, et al. Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: A multicenter randomized controlled trial[J]. Hepatol Int, 2021, 15(3): 741-752.
|
| [5] |
Li J, Wei M, Zeng Y, et al. Efficacy of endoscopic therapy combined with partial splenic embolization versus Hassab’s operation for patients with liver cirrhosis with esophageal variceal bleeding and hypersplenism: A multicenter cohort study based on propensity score matching[J]. Surg Endosc, 2024, 38(10): 5723-5731.
|
| [6] |
Dincer BT, Urganci N, Bayrak AH, et al. The role of partial splenic artery embolization in the management of refractory esophageal variceal bleeding due to portal vein thrombosis[J]. BMC Pediatr, 2025, 25(1): 49.
|
| [7] |
Wu ZZ, Deng WW, Zhu SW, et al. Erythroid progenitor cell-mediated spleen-tumor interaction deteriorates cancer immunity[J]. Proc Natl Acad Sci U S A, 2025, 122(9): e2417473122.
|
| [8] |
Zhao HC, Chen CZ, Song HQ, et al. Single-cell RNA sequencing analysis reveals new immune disorder complexities in hypersplenism[J]. Front Immunol, 2022, 13: 921900.
|
| [9] |
Liu C, Wang L, Xu M, et al. Reprogramming the spleen into a functioning ‘liver’ in vivo[J]. Gut, 2022, 71(11): 2325-2336.
|
| [10] |
Yang T, Zhang Y, Duan C, et al. CD300E(+) macrophages facilitate liver regeneration after splenectomy in decompensated cirrhotic patients[J]. Exp Mol Med, 2025, 57(1): 72-85.
|
| [11] |
Leideck P, Nkontchou G, Elkrief L, et al. The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience[J]. Clin Res Hepatol Gastroenterol, 2024, 48(6): 102355.
|
| [12] |
Hu YB, Duan L, Liu GY, et al. Clinical application of preoperative volumetric measurement for interventional precise embolization in the treatment of hypersplenism caused by liver cirrhosis[J]. BMC Surg, 2025, 25(1): 270.
|
| [13] |
Sun L, Tian J, Gu W, et al. Stepwise partial splenic embolization for the management of extreme splenomegaly[J]. Asian J Surg, 2025, 48(4): 2596-2597.
|
| [14] |
Lu H, Zheng C, Liang B, et al. Quantitative splenic embolization possible: application of 8Spheres conformal microspheres in partial splenic embolization (PSE)[J]. BMC Gastroenterol, 2021, 21(1): 407.
|
| [15] |
Zhao K, Hu HT, Li HL, et al. Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma[J]. PLoS One, 2025, 20(5): e0323829.
|
| [16] |
Kolb JM, Samarasena JB. EUS-guided splenic artery embolization for variceal hemorrhage: balancing creativity and innovation in endo-hepatology with caution[J]. Gastrointest Endosc, 2022, 95(1): 184-186.
|
| [17] |
Zaitoun MMA, Basha MAA, Elsayed SB, et al. Comparison of three embolic materials at partial splenic artery embolization for hypersplenism: clinical, laboratory, and radiological outcomes[J]. Insights Imaging, 2021, 12(1): 85.
|
| [18] |
Gao H, Sun B, Li X, et al. Risk factors for portal vein system thrombosis after partial splenic embolisation in cirrhotic patients with hypersplenism[J]. Clin Radiol, 2023, 78(12): 919-927.
|
| [19] |
Huang L, Li QL, Yu QS, et al. Will partial splenic embolization followed by splenectomy increase intraoperative bleeding?[J]. World J Gastrointest Surg, 2024, 16(2): 318-330.
|
| [20] |
Schultz G, Naas M, Webb J. Use of partial splenic embolization following a transjugular intrahepatic portosystemic shunt to reduce persistent portal hypertension sequelae[J]. Cureus, 2025, 17(8): e89540.
|
| [21] |
Wan YM, Li YH, Xu ZY, et al. Comparison of TIPS alone and combined with partial splenic embolization (PSE) for the management of variceal bleeding[J]. Eur Radiol, 2019, 29(9): 5032-5041.
|
| [22] |
Liu J, Yao W, Bai Y, et al. Optimal timing for TIPS and PSE combination treatment in patients with cirrhosis-related variceal bleeding and hypersplenism[J]. Acad Radiol, 2025, 32(3): 1534-1546.
|
| [23] |
Ishikawa T, Terai N, Sato R, et al. Partial splenic embolization for portal hypertension exacerbation during atezolizumab/bevacizumab combination therapy in unresectable hepatocellular carcinoma[J]. In Vivo, 2025, 39(2): 936-941.
|
| [24] |
Beppu T, Masuda T, Imai K, et al. Clinical benefits of partial splenic embolization for cancer patients[J]. Hepatol Res, 2025, 55(1): 4-11.
|
| [25] |
Hong W, Wang Z, Yao W, et al. Efficacy and safety of transarterial chemoembolization and repeated partial splenic embolization for hepatocellular carcinoma with hypersplenism and thrombocytopenia[J]. J Hepatocell Carcinoma, 2024, 11: 1065-1078.
|
| [26] |
DuBois B, Mobley D, Chick JFB, et al. Efficacy and safety of partial splenic embolization for hypersplenism in pre-and post-liver transplant patients: A 16-year comparative analysis[J]. Clin Imaging, 2019, 54: 71-77.
|